和元生物：2025年营收增长7.86%至2.68亿元，各主营业务板块均实现收入不同程度增长

Core Viewpoint - The company reported a significant reduction in net losses for the fiscal year 2025, indicating improved operational efficiency and revenue growth across its main business segments [1] Financial Performance - The total operating revenue for the company reached 268 million yuan, representing a year-on-year increase of 7.86% [1] - The net loss attributable to the parent company was 221 million yuan, which is an improvement compared to a loss of 322 million yuan in the same period last year [1] Operational Insights - All main business segments of the company achieved varying degrees of revenue growth during the reporting period [1] - The company increased its investment in research and development and focused on the application of technology, particularly through AI+ technology, to enhance R&D efficiency [1] - Operational costs and period expenses decreased compared to the same period last year due to these improvements [1] Cost Structure - Despite the improvements, the company still faced high fixed operational costs due to the large scale of asset operations at the Lingang base, including depreciation, energy consumption, and daily maintenance [1] - Overall profit remains negative, but the extent of the losses has significantly narrowed [1]